HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation

Increasing fetal hemoglobin (HbF) provides clinical benefit in patients with sickle cell disease (SCD). We recently identified heme-regulated inhibitor (HRI, EIF2AK1), as a novel HbF regulator. Because HRI is an erythroid-specific protein kinase, it presents a potential target for pharmacologic inte...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Peslak, Scott A., Khandros, Eugene, Huang, Peng, Lan, Xianjiang, Geronimo, Carly L., Grevet, Jeremy D., Abdulmalik, Osheiza, Zhang, Zhe, Giardine, Belinda M., Keller, Cheryl A., Shi, Junwei, Hardison, Ross C., Blobel, Gerd A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2020
Schlagworte:
Red Cells, Iron, and Erythropoiesis
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509868/
https://ncbi.nlm.nih.gov/pubmed/32956454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002475
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge